GRACE :: News/Info
GRACE Video

Faculty Expert Videos from IASLC Targeted Therapies in Lung Cancer Conference

Share
download as a pdf file Download PDF of this page

 

Here’s the growing list of videos done at the International Association for the Study of Lung Cancer (IASLC) 13th Annual Targeted Therapies in Lung Cancer meeting.

 

Dr. William Pao (Vanderbilt) on the My Cancer Genome Project

Dr. Geoffrey Oxnard (Dana Farber): What is an Inherited EGFR T790M Mutation, and What Does It Mean?

Dr. Lecia Sequist (Massachusetts General Hosp) on Molecular Marker Testing in Advanced NSCLC: What, Who, and When?

Dr. David Spigel (Sarah Cannon Cancer Ctr): What are the Most Promising Targeted Therapies for Lung Cancer in the Next Few Years?

Dr. Greg Riely (Memorial Sloan-Kettering): How Should We Approach Acquired Resistance to Targeted Therapies in Advanced NSCLC?

Dr. Heather Wakelee (Stanford): How Should We Use Molecular Marker Information for Management of Earlier Stage Non-Small Cell Lung Cancer?

Dr. Karen Kelly (Univ. California, Davis): What Molecular Markers Do You Routinely Send for in Your Patients with Advanced Non-Small Cell Lung Cancer?

Dr. Sarah Goldberg (Yale): How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?

Drs. Ross Camidge (Univ. of Colorado) and Corey Langer (Univ. of Pennsylvania) Who Do You Recommend Repeat Biopsy for if There Isn’t Enough Tissue for Molecular Testing?

Dr. Bob Doebele: Will We Be Able to Use Molecular Markers and Apply Targeted Therapies to Broader Lung Cancer Subtypes in the Near Future?

Dr. Phil Bonomi: Is Maintenance Therapy after First Line Chemotherapy a Mandate, An Option, or a Neither?

Dr. Alan Sandler: Is There a Danger that the Latest Advances in Molecular Testing Are Only Available in Limited Specialty Settings?

Dr. Ravi Salgia on Management Strategies for Acquired Resistance to Targeted Therapies, Single Focus or More Diffuse

Dr. Rosalyn Juergens: What Novel Therapies Are You Most Optimistic About as Potential Lung Cancer Treatments in the Next Few Years?

Dr. WIlliam Pao on the Goals for Developing MyCancerGenome.org

Dr. Karen Reckamp: Recommending a Repeat Biopsy, at Initial Diagnosis or with Acquired Resistance to a Targeted Therapy

Dr. Geoffrey Oxnard on Managing Acquired Resistance to EGFR Inhibitor Therapy (and Probably Crizotinib, Too)

Dr. Greg Riely: How I Use Molecular Marker Information in Earlier Stage NSCLC Patients

Dr. Lecia Sequist: Can We Bring The Advances in Targeted Therapy to Squamous NSCLC and Broader NSCLC Populations?

Dr. Monty Pal on the Current Best Practices for Early Stage Kidney Cancer

Dr. Larry Einhorn: How Can We Replicate the High Cure Rates We’ve Achieved for Testicular Cancer in a Wide Range of Cancers?

Dr. Larry Einhorn: Will Costs of Care Limit Our Ability to Deliver Cancer Treatments?

Dr. David Spigel: Which Lung Cancer Patients Should We Be Doing Molecular Marker Testing For, and Should We Do “Reflex Testing”?

Drs. Ross Camidge and Corey Langer: Which New Targets and Therapies Could We Bring to the Lung Cancer Clinic in the Near Future?

Dr. Sarah Goldberg: The Potential Value of a Treatment Break as an Alternative to Maintenance Therapy in Advanced NSCLC

What Molecular Markers Do You Prioritize for Molecular Testing in Advanced NSCLC, and Who do you Test?

Do You Seek and Do You Use Molecular Marker Information in Patients with Early Stage NSCLC?

Dr. Pal on the Role of Interleukin-2 (IL-2) in Advanced Kidney Cancer Today

Dr. Monty Pal: Reviewing Bladder Cancer Stages, the Role of Surgery, and the Potential Role of Chemotherapy for Localized Bladder Cancer

Dr. Sandler on Options for Maintenance Therapy: Switch, Continuation, or a Treatment Break?

Dr. Rosalyn Juergens on Managing Acquired Resistance to Targeted Therapies for Advanced NSCLC

Dr. Karen Reckamp: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

Dr. Heather Wakelee: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing

Dr. Geoffrey Oxnard on Translating the Benefits of Molecular Oncology More Broadly: The Tissue is the Issue

Dr. Monty Pal on Leading Options for First Line Treatment of Advanced Kidney Cancer

Dr. Larry Einhorn: What are the Biggest Challenges We Face in Delivering Effective Cancer Care in the Next Decade?

Dr. William Pao on “How Concerned Should We Be About Different Testing Methods, as well as the Heterogeneity of Different Biopsy Results from the Same Patient?”

Dr. Ravi Salgia on “My Approach to Maintenance Therapy for Advanced NSCLC

Dr. Greg Riely on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment

Dr. Alan Sandler: My Approach to Acquired Resistance for Targeted Therapies in Lung Cancer

Dr. Natasha Leighl’s Highlights in Lung Cancer from 2012: Developments for EGFR Mutation-Positive NSCLC

Dr. David Spigel: We’ve Probably Made Maintenance Therapy More Complicated Than It Needs To Be

What is the Right Surgery for Early Stage Kidney Cancer?, by Dr. Monty Pal

Drs. Ross Camidge and Corey Langer: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?

Dr. Heather Wakelee on the Most Promising New Agents and Pathways for Treating Lung Cancer in the Coming Years

Dr. Lecia Sequist on Relevant Emerging Molecular Targets in Lung Cancer

Dr. Sarah Goldberg on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer

Dr. Geoffrey Oxnard on What Molecular Markers to Test for in Advanced NSCLC, and in Whom?

Dr. Greg Riely on “I just found out I have an EGFR mutation, and I’m in the middle of chemo. What now?”

Dr. Karen Reckamp on “Which patients do you send molecular marker testing for, and what tests do you seek?”

Dr. Ravi Salgia: How Do I Discuss the Side Effects of Targeted Therapies, as Compared with Chemotherapy?

Dr. Heather Wakelee: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?

Dr. Lecia Sequist: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?

Drs. Ross Camidge and Corey Langer: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

Dr. Sarah Goldberg: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy

Dr. David Spigel on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer

Dr. Karen Kelly on “My Approach to Maintenance Therapy for Advanced NSCLC

Dr. Phil Bonomi on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment

Dr. Greg Riely on Muliplex Next Generation Sequencing and its Effect on Molecular Oncology Practice

Dr. Geoffrey Oxnard: Are Patients or Payers Objecting to Repeat Biopsy?

Dr. Ravi Salgia on “Which patients do you send molecular marker testing for, and what tests do you seek?”

Dr. Larry Einhorn on “What Have Been the Most Significant Changes in Cancer Care over the Past Decade or Two?”

Dr. Rosalyn Juergens on “I Just Found Out I Have an EGFR Mutation, and I’m in the Middle of Chemo. What Now?”

Dr. Lecia Sequist: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?

Dr. Sarah Goldberg: What Methods Do I Use to Obtain Samples for Molecular Testing?

Dr. David Spigel: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing

Dr. Karen Kelly on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment

Dr. Phil Bonomi, Rush University: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

Dr. Sumanta (Monty) Pal on the Role of Chemotherapy in the Treatment of Kidney Cancer

Drs. Ross Camidge and Corey Langer: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?

Dr. Greg Riely: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy

Dr. Rosalyn Juergens on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer

Dr. Lecia Sequist on Multiplex Next Generation Sequencing and its Effect on Molecular Oncology Practice

Dr. Sarah Goldberg: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?

Dr. David Spigel: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?

Dr. Karen Kelly: Do You Continue a Treatment Beyond 4-6 Cycles to Exhaust its Benefit?

Dr. Geoffrey Oxnard on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment

Dr. Ravi Salgia on the CollabRx System for Matching Patients with Mutations to Clinical Trials

Dr. Larry Einhorn: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?

Drs. Ross Camidge and Corey Langer on “Which patients do you send molecular marker testing for, and what tests do you seek?”

Dr. Sumanta (Monty) Pal: What is the Role of Surgery in the Treatment of Metastatic Kidney Cancer?

Dr. Phil Bonomi, How Do I Discuss the Side Effects of Targeted Therapies, as Compared with Chemotherapy?

Dr. Greg Riely on “My Approach to Maintenance Therapy for Advanced NSCLC

Dr. Sarah Goldberg on “I Just Found Out I Have an EGFR Mutation, and I’m in the Middle of Chemo. What Now?”

Dr. Rosalyn Juergens: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy

Dr. David Spigel: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?

Dr. Karen Kelly: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing

Dr. Ravi Salgia: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

Dr. Larry Einhorn: Are You Optimistic That a Supercomputer Such as Watson Will Be Able To Improve Cancer Care?

Dr. Sumanta (Monty) Pal: What Are the Options for Second Line Treatment of Kidney Cancer?

Dr. Heather Wakelee on “My Approach to Maintenance Therapy for Advanced NSCLC

Dr. Sarah Goldberg on “Which molecular marker tests do you seek?”

Dr. Rosalyn Juergens: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?

Dr. David Spigel: How Do I Discuss the Side Effects of Targeted Therapies, as Compared with Chemotherapy?

Dr. Phil Bonomi: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?

Dr. Karen Kelly: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy

Dr. Greg Riely: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing

Dr. Sumanta (Monty) Pal: What Are the Main Types of Kidney Cancer and Are They Managed Differently?

Dr. Heather Wakelee: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

Dr. David Spigel: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?

Dr. Ravi Salgia: What is Your Opinion of Patients and Caregivers Searching the Internet for Information?

Dr. Sarah Goldberg on “Which patients do you send molecular marker testing for?”

Dr. Rosalyn Juergens on “My Approach to Maintenance Therapy for Advanced NSCLC

Dr. Geoffrey Oxnard: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy

Dr. Greg Riely: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

Drs. Ross Camidge and Corey Langer: How Do You Make Use of a Broad Molecular Profile Brought by a Patient?

Dr. Phil Bonomi: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?

Dr. Karen Kelly: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?

Dr. Larry Einhorn: What is Your Opinion of Patients and Caregivers Searching the Internet for Information?

Dr. Heather Wakelee on “Which molecular marker tests do you seek?”

Dr. David Spigel: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

Dr. Geoffrey Oxnard: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?

Dr. Rosalyn Juergens: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?

Dr. Phil Bonomi: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy

Dr. Greg Riely: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?

Drs. Ross Camidge and Corey Langer on “Which patients do you send molecular marker testing for?”

Dr. Bob Doebele on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment

Dr. Sarah Goldberg: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

Dr. Ravi Salgia: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?

Dr. David Spigel on “Which molecular marker tests do you seek?”

Dr. Philip Bonomi: Gefitinib and Later Generations of EGFR Inhibitors

Dr. Bob Doebele: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?

Dr. Greg Riely on “Which patients do you send molecular marker testing for, and what tests do you seek?”

Dr. Rosalyn Juergens: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

 

We thank these experts for their generosity with their time and expertise in providing this information to the lung cancer community.


6 Responses to Faculty Expert Videos from IASLC Targeted Therapies in Lung Cancer Conference

  • ssflxl says:

    Dr West

    I hope you take some ‘down time” to spend outdoors – take a walk, breath the air. We want you in good shape here.
    thanks so much

    ssflxl

  • Dr West
    Dr West says:

    That’s the unfortunate part. I’ll be in Santa Monica but probably will barely get outside of the hotel for more than a stray break. Our meals are within the hotel, and I’m doing meetings and video interviews starting at 6 AM some days and then after our dinners. It’ll be semi-social (even mostly social), but I think I’ll barely have any time to avail myself of the good trade in terms of weather between Seattle and LA.

    And while I’m working to make a commitment to an hour of daily exercise (real cardio exercise), I did it this morning before leaving and plan to do it upon my return Saturday but don’t think I can do it Thursday or Friday because I couldn’t fit the extra shoes and clothes in my carry on with all of the A/V stuff I’ve got, and I realized I really won’t be able to carve out the time while I’m at this conference.

    I’ll live. I can get more exercise and rest when I’m back home. But thanks for the sentiment.

    -Dr. West

  • Jazz says:

    Looking forward to your report(s)! Thank you for your dedication… trading AV equipment for workout clothes! In LA, no less. Have a wonderfully productive time.

    Jazz

  • Jazz says:

    Dr. West,

    Wow, thanks for all the videos! How terrific that you were able to corral all the participants into doing their blurbs, and thanks to the doctors for their bits of wisdom.

    I’m guessing you didn’t have one minute for celebrity sightings, being there on Oscar week and all…

    Jazz

  • Dr West
    Dr West says:

    You know, the meeting is always the same week, right before the Oscars, and every year I forget that, come home and remember about the Oscars, and then am disappointed that Angelina Jolie didn’t bump into me and ask for my autograph.

    But then I remember that this is very unlikely to happen if we barely step out of the hotel. I’m sure she’d have approached me otherwise.

    -Dr. West

  • wadvocator says:

    Since we live in the same city and if I bump into you, I will ask for your autograph. But I guess that is not the same as Angelina Jolie.

Leave a Reply

Ask Us, Q&A

GRACE Is Here To Help

Archives

Share
download as a pdf file Download PDF of this page

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Share
download as a pdf file Download PDF of this page

Join the GRACE Faculty

Lung/Thoracic Cancer Blog
Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
Share
download as a pdf file Download PDF of this page

Subscribe to the GRACEcast Podcast on iTunes

Share
download as a pdf file Download PDF of this page

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Recent Posts

Other Resources

Share
download as a pdf file Download PDF of this page

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243